

March 8, 2016

NEMUS Bioscience CEO to Present at the 28th Annual ROTH Conference

Presentation to Take Place on Wednesday, March 16, 2016 From 10:00 to 10:30 AM PDT

COSTA MESA, CA -- (Marketwired) -- 03/08/16 -- [NEMUS Bioscience, Inc.](#) (OTCQB: NMUS), a biotech company focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs, today announced that Brian Murphy, MD, NEMUS Bioscience's CEO and CMO, will present at the 28th Annual ROTH Conference. The conference will be held March 13-16, 2016 at The Ritz Carlton Hotel in Dana Point, CA.

EVENT: 28th Annual ROTH Conference

DATE: Wednesday, March 16, 2016

TIME: 10:30 AM PDT

LOCATION: Ritz Carlton, Dana Point, CA, Salon 5 - Pink

To schedule a meeting with management, please contact Adam Holdsworth at 646-862-4607, or adamh@pcgadvisory.com.

ABOUT NEMUS BIOSCIENCE, INC.

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS' strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit <http://www.nemusbioscience.com>.

FORWARD LOOKING STATEMENTS

Statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties, including statements about the potential benefits of cannabinoid-based medicine and the timing of our near term, intermediate term and long term goals. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively

affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS' most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

CONTACT:

PCG Advisory Group

Investor Relations

Adam Holdsworth

Email: adamh@pcgadvisory.com

Phone: 646-862-4607

Media Relations

Sean Leous

Email: sleous@pcgadvisory.com

Phone: 646-863-8998

Source: NEMUS Bioscience, Inc.